RT Journal Article SR Electronic T1 Resveratrol And Pterostilbene Potently Inhibit SARS-CoV-2 Infection In Vitro JF bioRxiv FD Cold Spring Harbor Laboratory SP 2020.09.24.285940 DO 10.1101/2020.09.24.285940 A1 B.M. Ellen ter A1 N. Dinesh Kumar A1 E.M. Bouma A1 B. Troost A1 D.P.I. Pol van de A1 H.H. Ende van der-Metselaar A1 L. Apperloo A1 D. Gosliga van A1 M. Berge van den A1 M.C. Nawijn A1 P.H.J. Voort van der A1 J. Moser A1 I.A. Rodenhuis-Zybert A1 J.M. Smit YR 2020 UL http://biorxiv.org/content/early/2020/09/24/2020.09.24.285940.abstract AB The current COVID-19 pandemic is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and has an enormous impact on human health and economy1. In search for therapeutic options, researchers have proposed resveratrol, a food supplement with known antiviral, anti-inflammatory and anti-oxidant properties as an advantageous antiviral therapy for SARS-CoV-2 infection2–4. Here, we provide evidence that both resveratrol and its metabolically more stable structural analog, pterostilbene, exhibits potent antiviral properties against SARS-CoV-2 in vitro. Resveratrol and pterostilbene showed antiviral activity in African green monkey kidney cells and in human primary bronchial epithelial cells cultured in an air-liquid interface system. Mechanistic analyses demonstrated that both compounds actively interfere with the post-entry steps of virus replication cycle and their antiviral activity is long-lasting. Collectively, our data indicate that resveratrol and pterostilbene are promising antiviral compounds to treat SARS-CoV-2 infection and advocate evaluation of these compounds in clinical trialsCompeting Interest StatementThe authors have declared no competing interest.